regeneron is a bridge to a vaccine.ott testing, which i continue to believe is undervalued in this market because it's only $5, is going to give you a chance to show that you don't have covid, you can test every single day, i mean, obviously you don't have covid today, you get covid tomorrow what did we learn from the tennessee titans, every one of those guys was tested right before the game and then they tested after the game and it was no go. the one that i was hoping david would shoot down and he hasn't is the duke energy alleged deal which, david, i am told is not a real deal. >> you're told it's not real i have no reporting on it for you yet. i found out about it like a lot of people did, by reading the "wall street journal." >> but, david -- >> there was an approach made -- >> the journal says that next tara will come back but i haven't seen duke's share price. >> it would be hostile they don't do hostile deals. >> it does point to potential consolidation of that industry they have been an aggressive acquirer real

doctor, thanks to regeneron for everything you're doing.y, thanks as well. >>> president trump's war on voting. will he launch new attacks during tonight's debate? we'll be right back. and get matched with a customized plan. the assessment takes into account the things that matter to you the most. on my plan, whole wheat pasta and potatoes are zero points. on the app, we love the personalized recipes. we found so many new favorites! with 24/7 live coaching, you get connected to an amazing coach, who can answer any question that you might have. i lost 91 pounds. it's the best thing i could've ever done! join today and get a free ww cookbook bundle! plus you could win an amazon halo band! in the tubbs fire. the flames, the ash, it was terrifying. thousands of family homes are destroyed in wildfires. families are forced to move and higher property taxes are a huge problem. prop 19 limits taxes on wildfire victims so families can move without a tax penalty. nineteen will help rebuild lives. vote 'yes' on 19. >>> ahead of tonight's debate, presi

right now, check out shares of regeneron. the company said the trial date of the antibody cocktail improved levels and fighting the virus. the company's cofounder and president will join us in the 7:00 hour. we'll be right back. everyone wakes up every morning to a world that must keep turning. the world can't stop, so neither can we. because the things we make, help make the world go round. they make it cleaner, healthier, and more connected. it's what we build that keeps things moving forward. so with every turn, we'll keep building a world that works. ♪ you can go your own way ♪ go your own way your wireless. your rules. only xfinity mobile lets you choose shared data, unlimited or a mix of each. and switch anytime so you only pay for the data you need. switch and save up to $400 a year on your wireless bill. with the carrier rated #1 in customer satisfaction. call, click, or visit your local xfinity store today. >>> disney has announced it is laying off 28,000. the prolonged closures at theme parks and limited attendance

frankly, our partnership with regeneron, we have the ambition to be over $11 billion but we're stillof transforms lives and you're right when you say we've made some acquisitions we want to be a big player in the back done in oncology. and we hope we're about to close off a deal, bringing the btk into play for multiple sclerosis. 35 other potentially transformational medicines or indications coming it's all about transformation. it's all about culture and bringing everything through, so that we get that practice changing medicine. it's a big deal for us it's huge and we're really proud of the progress we're making >> i want to quote you, because i want people to understand you and your company you talk about no matter what, in reference to the covid-19 vaccine, and i think it's your company, you want to maintain purity of purpose, simplification and problem solving. is that your m.o.? >> no company i would put it to you feels closer to its purpose right now. we're the only company with two covid-19s, and we're bringing these transformational medicines through, despite the pandemic an

. >> when we come back, why general motors says it is sticking by nikola and why shares of regeneron are surging this morning later on, a first-hand look at indoor dining in the big apple we speak with one restaurant owner with a lot on the line ♪ >>> welcome back let's get a check on some of the stocks on the move today general motor says it is continuing their discussion with nikola when the deal was announced, nikola expected it to close before september 30. since then, the founder resigned after the company accused of fraud. nikola denied allegations. you can see general motor shares up, nikola down. >> regeneron drug helps threat covid-19 in early stages preliminary results could produce an eua from the fda that may allow the drug to be prescribed the company's cofounder and chief scientific officer will join "squawk box" this morning at 7:20 a.m. eastern time. >> micron expects to see significant sales hit this quarter d quarter primarily due to shipments to huawei. shares off 4.5% pre-market >>> still on deck, the nearly 20 year wait is over on wall street as the once secret p

the us company regeneron, behind this covid treatment, have used the technology to successfully treat ebola. there are high hopes. we are very excited about our antibody combination. these highly potent neutralising antibodies really will help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don't want to neglect. covid cases are rising and the timescale of the recovery trial depends on the rate of hospital admissions. only then will we see if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. an international team of astronomers say they've found the strongest evidence yet that life may exist on the planet venus. they've detected traces of a gas in its atmosphere which they believe could be produced by living microbes. and although the team say there could be another explanation for the presence of the gas they've yet to come up with one, as our science correspondent pallab ghosh explains. venus. could it be home to extra terrestrial life? the

this is regeneron's antibody cocktail and early results seem to show that this cocktail does lower the level of the virus and also improve symptoms. but, wolf, you know, we are getting better at treating this disease, but as you just laid out, the virus is still out there and spreading fast. new york city. biggest district in the nation reopened elementary schools this morning. but nearly half of students have chosen to stay home for now to learn online only. staff in 150 school buildings have tested positive. >> it is creating a lot of anxiety for the teachers because it's a lot of unknown, right? it's a lot of uncertainty. >> reporter: the nypd now handing out masks hoping to staunch flare-ups in parts of the city. the mayor mulling reintroducing restrictions in nine zip codes. >> which would be the closing of businesses on some scale. and a broader closing of community institutions. we do not want to do that if there's any way to avoid that. >> reporter: meanwhile, "the new york times" reports the white house put pressure on the cdc to downplay the risk of sending kids back to schoo

but vaccines are coming and so are treatments just tonight a company you visited, lester, regener regeneron announced encouraging results for a cocktail that reduces the severity of covid essentially meaning fewer hospitalizations >>> there is also promising news about a leading covid vaccine candidate, a small study found that older people who got moderna's vaccine produced immune responses similar to those in younger adults important because older people are especially at risk it is one of five candidates currently in final trials. >>> coming up, inside the first airport rolling out its own covid testing. >>> tonight the first covid outbreak in the nfl. three players on the tennessee titans testing positive along with five others who work for the team. both the titans and the minnesota vikings who faced each other on sunday suspended in-person activities for the time being their games next weekend are uncertain. >>> in the search for solutions tonight, making flying during the pandemic safer kerry sanders goes inside the first u.s. airport offering covid testing to travelers >> reporter:

as you can see, there is pressure on sanofi, there is pressure on regeneron. >>> let's go back to the, the dow is up 134 points. we are in positive territory for 2020 if we hold at these levels. we shall see. >>> bloomin brands getting beefed up. deutsche bank turning bullish. pun intended. okay? i had to do it. on the outback steakhouse parent's long-term prospects. raymond james going even further, calling shares a strong buy. it's currently up 13% and change. >>> to the flipside, as farmers continue to face [ inaudible ] could the heartland be the ultimate spoiler in november? we will talk to a fifth generation farmer and chairman of the nation's growers council is up next. we'll be right back. so you're a small business, or a big one. you were thriving, but then... oh. ah. okay. plan, pivot. how do you bounce back? you don't, you bounce forward, with serious and reliable internet. powered by the largest gig speed network in america. but is it secure? sure it's secure. and even if the power goes down, your connection doesn't. so how do i do this? you don't do this. we do this, toge

the us company regeneron, behind this covid treatment, have used the technology to successfully treatl help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don‘t want to neglect. covid cases are rising and the timescale of the recovery trial depends on the rate of hospital admissions. only then will we see if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. the american software company, oracle, has confirmed it wants to create a partnership with the video—sharing app, tiktok. the us administration is now reviewing oracle‘s bid, having previously said chinese ownership posed a threat to national security. frank lavin is a former us undersecretary of commerce under president george w bush. i asked him how much the us had to be concerned about over security issues. i think there is enormous concern on our security front. the concern of applications like tick—tock or companies like tick—tock or companies like wei wei collect a lot of data. —— h

the us company regeneron, behind this covid treatment, have used the technology to successfully treates. we are very excited about our antibody combination. these highly potent neutralising antibodies really will help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don't want to neglect. covid cases are rising and the timescale of the recovery trial depends on the rate of hospital admissions. only then will we see if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. people have been making the most of the sunshine and unseasonable warmth in france. temperatures are forecast to be io- temperatures are forecast to be 10-15 temperatures are forecast to be 10 — 15 degrees above average for the sum of years. they revealed a number of september hit records on monday. one area hit records on monday. one area hit 35.6 degrees, its hottest september day since 1961. an international team of astronomers say they've found the strongest evidence yet that

-- regeneron has highly potent neutralizers, i just think it's september, carl, and the clock seemso be ticking for a lot of these small businesses excellent piece, excellent piece on "squawk" this morning about how the small businesses are being hurt so much when was the last time we traded a small business and the answer is we don't because they're not public >> yep, the big blind spot that public equities have that we have talked about for a long time the president last night, jim, throwing out the three to four week timeline on at least the introduction of a vaccine. so i guess we have to sort of throw that in the mix despite what others in the industry and at nih talk about being in terms of the end of the year instead. >> maybe it's entirely possible that the trials are not in the thick of things in new york because our rate is so low and what you really need are people in hot spots there's only one active -- i mean, i've called all the drug companies, the only one active trial that i know i can get in is in the moderna trial, almost all the other trials are just not in new yo

the us company regeneron, behind this covid treatment, have used the technology to successfully treatd about our antibody combination. these highly potent neutralising antibodies really will help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don't want to neglect. covid cases are rising and the timescale of the recovery trial depends on the rate of hospital admissions. only then will we see if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. the labour leader sir keir starmer says he's self—isolating at home after a member of his household developed coronavirus symptoms. sir keir found out about the concerns following an appearance on lbc radio this morning. he's not reported to have shown any coronavirus symptoms himself. his family member has been tested and is waiting for the results. the government has faced fierce attacks in the commons over its plans to override international law and change the brexit divorce deal. it comes as david

the us company regeneron, behind this covid treatment, have used the technology to successfully treated about our antibody combination.

there is one right now by regeneron.trongly, important to incorporate three or more antibodies into these cocktails. if you do so with a focus on safety in particular and efficacy. emily: so, if you're a patient who has been infected, you have covid-19, you take your antibody cocktail. what happens? jennifer: so, initial applications for patients will probably be iv administered. but basically what happens is if you are a patient who is already with the disease, hope it is it will prevent the virus from spreading throughout the body by of infecting any new cell. emily: talk to us about what this means. as we work towards a vaccine, if we have a successful antibody treatment now essentially, then the urgency of a vaccine -- we don't need it right away, correct? how could this change the game? jennifer: we definitely do believe absolutely both are important, but there are some ways it does change in terms of how we respond to a number of different scenarios. one is patients or individuals who might have been exposed to the

the us company regeneron behind this covid treatment have used the technology to successfully treat ebolathese highly potent neutralising antibodies really will help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don't want to neglect. with covid cases rising, new treatments will be essential. the recovery trial will tell us if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. it's a british company whose technology is at the heart of most smartphones — as well as many other devices. but there are fears that chip designer arm holdings‘ sale to an american firm could mean many jobs going abroad. the cambridge—based company is being sold by its japanese owners for more than £30 billion to nvidia — one of arm's clients. rory cellan—jones is our technology correspondent. we may not have heard of the name but we know about its products? yes, simon, arm is probably the most exciting and important technology firm that has surfaced in the uk over the la

has had exposure but has not developed the disease, they -- it is exciting to see the news from regeneronk of these as a bridge. we are waiting for a vaccine, we can use these -- early, which is a good tool in the tool kit for sure. hopefully, we will see that move toward either approval or emergency -- depending on the data. seconds, the j0 and to vaccine as one does come i that make a difference? important to have one dose vaccines because with the follow-up, we lose people. we know we lose people and that is a consistent way in which the vaccine is not complete. if we can have a one dose vaccine that can be rolled out and you get it any move on, that makes it easier. thank you so much for joining us. she is from johns hopkins. you can tune in every day for our exclusive conversations with johns hopkins experts for an inside look at battling covid-19. up next, more "bloomberg: surveillance." this is bloomberg. ♪ ♪ bull market that is under some pressure. >> we are probably getting towards the low end of this correction phase. >> investors are starting to show more bearish sentiment. >>

we know how to treat this virus a lot better now anything like this regeneron drug are going to make the outcomes that much better for people i think the surprise is to the positive side. the i think we're going to outnumber the surprises to the negative side on this. st. >> jason, do we not see a massive rally in the cyclicals in it terms of pharmaceutical industry related news until we have a vaccine and you are overall a little bit more fearful >> wilf, this is certainly helpful. the best stimulus we can have is a vaccine or reopening of the economy. much better than fiscal stimulus from the government or monetary stimulus it can help, certainly but getting people back in the service parts of the economy i think it is critical to getting the economy on the right footing and to getting the cyclicals doing quite a bit better the manufacturing side of the economy is doing quite well. you say a look at semiconductor. you are producing more it is greater than the pandemic. but in order to get services to come back, you obviously have to have much better news on consumer confidence. i h

susan: outperformance, regeneron rally and after results from the antibody cocktail therapeutic showinghelp people infected with covid would shake their symptoms faster and reduce the amount of viral load in their body. the patients with their own coronavirus antibody they sell symptoms become mild or absent in six days on average, 13 days on a placebo and that's only after a low dose, moderna is another vaccine developer and also up after early-stage data shows coronavirus vaccine can generate neutralizing antibodies and the more susceptible, they can be older and elderly folks and level compared to the antibody load in their body after the vaccine which i thought was very impressive. stuart: my problem with the vaccine, how many people actually take the vaccine when it is available. how many, how many are willing to take a. susan: elon musk even said he would not take one. stuart: i think that's going to be a problem. american airlines, lawrence got this one, the testing passengers for the virus before they get on the flight. lauren: yes, all about making you feel comfortable that nob

still early days, though, guys >> so let's toss this around guy, i'll go to you first with this regeneron. >> i guess the good news is it's probably sold off 60 or $70, maybe 10 or 11% from the recent all-time high. maybe there's an opportunity to get in depending on what it looks like on the reopen the entire space has been really interesting. eli lilly is up considerably from its all-time high gilead has been a trough now for the last couple years. i have no idea what moderna is doing, if it's high or low in the after hours. in terms of the broader market, is this the news that's going to get us back to that 3393 level in the s&p is or is this a nonstarter for the markets to me, that's the most interesting thing out of all of this >> karen, are there names that stand out to you, the ones you feel are more promising, whether they be on the spectrum of vaccine or treatment or anything else >> there's are the vaccines promising and there's a question of do you want to own the stock. do i want to own the stock definitely not you've seen names like moderna up huge and then down. even if they

see names like ertex, regeneron, biogen and amgen. the growth names getting hit harder one interesting trend you're seeing is a drag among names that are in the diagnostic space and the tool space like bio rad. among the bigger pharma names, you are seeing weakness. pfizer is expecting to get data in october dr. fauci says that looks pretty optimistic >> someone comes out and says i'm going to shoot for the possibility that i'll get it by october, you can't argue strongly against that. that is unlikely not impossible i think most of the people feel it will be november, december. >> an october surprise would be an optimistic sfriez for vurpri. >>> let's take a look at the dow which is down more than 800 points short of 3%. the losses are worse in a percentage basis for the nasdaq. it's shutting nearly 5% today. up next we'll look ahead to tomorrow's job report. whether that's a catalyst for sochl t some of the selling we're seeing now. stay with us >>> today's weekly jobless claims number came in better than expected. the number comes

couple from eli lily, regeneron, roche and a steroid there. which one looks more promising. if vaccine is not the answer, treatment is >> i'll tart first. these are two different answers to covid-19. if we want our lives to return back to some semblance of normal we'll have to either enact real public health interventions like contact tracing and testing or have a vaccine in place. treatment is really critical to make sure if people are infected by the coronavirus which causes covid-19 that they are not getting extremely ill. most of these new treatments are focused on early coronavirus with symptoms that are light rather than the heavy symptoms that leads someone to hospital. that's good news. they come in a couple of different forms. there are some that sort of beat down the bodies immune response so your body doesn't go into overdrive hurting you while trying to kill the virus. some of them are antibody cocktails that neutralize the virus itself and there are a couple that are approaching phase three, into phase three, in fact, so we'll watch that. all of them have differ

to people that the vaccines there's also the -- there are also the monoclonal antibodies, that's regeneronthen there is the small molecule which is merck. antivirals i'm talking now those are antivirals as opposed to the vaccine we will talk about it every day until we actually get something out of phase three that gets approved or emergency usage, but then the question becomes, guys, who is going to take it, how quickly will they take it? manufacturing may be there but can you distribute it. you have all seen the 8,000 boeing whatever it is that would be needed and the minus 80 degrees fahrenheit. >> fedex is ready with those. >> are they? >> yes, they said it on the call. >> maybe it will happen. >> honeywell is ready with vials. >> you like to listen to dr. fauci and he didn't seem particularly optimistic for the idea of it being widely available next year. >> i think maybe we spent too much seem talking about one case that may or may not be related in what was supposed to be a very powerful vaccine. >> the astrazeneca, which has resumed. which has resumed. >> right and what i want to r

. >> and regeneron. >> which is a monoclonal. >> two very powerful opportunities.egeneron's stock is rolling over as if they have nothing, it's down 100 points from its high, but there is a number of stocks, carl, down 100 points from their high in this nasdaq and look like they're rolling over i was doing a comparison of some of these hot nasdaq stocks to a freeport which is a copper stock. >> yeah. >> if you look at the freeport chart it is -- it's what these nasdaq stocks looked like before the labor day selloff. >> sure. >> you are in the wrong ones if you're barking up brink central. david, this is not the time for z scaler. >> no, it may not be what about unity, though unity today will be another incredibly hot it would seem initial public offerings, maybe not quite on the level of snowflake a couple days ago, but not far. i'm hearing the same kind of enthusiasm, let's call it that. >> right. >> goldman sachs i think the lead underwriter -- >> when do they run out of money? are they just going to okta to ? >> maybe. >> sell some crowd strike? >> would you >>

melissa: "fox business alert," regeneron halted after-hours.ny saying its experimental anti-body cocktail reduced viral levels and reduced symptoms in patients with mild to moderate covid-19. adding it plans to rapidly discuss the trial results with regulatory authorities. hmmm. >>> just hours away from the first presidential debate. president trump and former vice president joe biden will go head-to-head on a number of issues tonight. hillary vaughn is live on the ground in cleveland, ohio with, the latest. hillary. reporter: melissa, president trump was the first to touch down here in cleveland ahead of tonight's debate. democratic nominee joe biden is on his way right now in the air from wilmington. he is expected to land in about half an hour from now. this will be the first face-to-face showdown between the two candidates but the backstage negotiations leading up tonight are leaking out. the trump campaign requested an ear check of each candidate before taking the stage tonight to confirm there won't be anyone talking in the candidate's ea

so this is regeneron, a company that you may have heard of.keeping an eye on for some time. and the product we're talking about here is something known as a monoclonal antibody. it's basically a couple of antibodies that are found to help neutralize this virus. they create a cocktail of these two antibodies, and they've been giving it to people in these very early trials, jake. and let me emphasize that. what i'm sharing with you has not been peer reviewed. it's only come to us through a press release. so we got to give these caveats. we wouldn't normally be talking about studies so early were we not in the middle of a pandemic. but what they showed was that in people who had symptoms but were not hospitalized, in this study it seemed to decrease the length of time that they had symptoms. and it seemed to decrease the amount of virus in their nose and their mouth. and that's really important because that would likely make them less contagious as well. i should point out the average age of people in this trial, 45 years old. i bring that up bec

regeneron last night. knew was massive. they have a bridge to the other side.t of recession. buy value stocks. you will do well owning value names. rotate to a degree from the large cap growth names. take some profits. go to value. skip small cap. too much pressure. do well in mid-cap. buy high quarter bonds. do that you will set up for great returns in the first quarter. charles: phil, we always hold you to account. you have a tremendous track record with us. thanks a lot, buddy. of course we'll stay on the markets as we wrap up the month, including the last trades you need to consider as we get away from september and go to october. but first house republicans are recommending a stiffer response to china's rise calling the communist country, quote, a generational threat. state department spokesperson morgan ortegas will weigh in. she's next. charles: house republicans say the china's evil intentions have gone on far too long and they are a generational threat. they have come up with 430 policy recommendations to help combat the theft, boosting medical supply

the us company regeneron behind this covid treatment have used the technology to successfully treat ebolar antibody combination. these highly potent neutralising antibodies really will help boost that immune response and will always be needed, even when a potent vaccine is available, because there are going to be underserved populations that we don't want to neglect. with covid cases rising, new treatments will be essential. the recovery trial will tell us if the promise of monoclonal antibodies turns into a reality. rebecca morelle, bbc news. joining us now is martin landray who is a professor of medicine and epidemiology at the university of oxford — he is co—leading on the recovery trial of artifical antibodies. you saw him in that report he is leading the trial. the first thing you would need is patients, have you got them yet? over the summer months tha nkfully got them yet? over the summer months thankfully covid has been relatively scarce in the uk and the number of patients coming into hospital has been really quite low. we're already rising case numbers in the community and as we

both stocks down, especially regeneron, down 3%.e final phase of the virus vaccine trials. nevertheless the stock is down 1.2%. >>> walmart, rolling out their wal-mart plus service. direct competition for amazon, ain't that right, susan? susan: they're definitely looking over their shoulder. talking about walmart plus, $98, slightly less than prime membership fee of $119. free grocery delivery, discount on gas at walmart parking lots. 10,000 items discount including toilet paper and fresh food. there is a cash, only items sold in store. walmart plus does not include free delivery from the online store, walmart.com. it sells millions of items and instead of hundreds of thousands of items. walmart.com, you get free delivery on any order over 35 bucks anyways. stuart: given that caveat the market still likes it. you're up, on walmart. the tiktok deal might be back on. susan: this is all impending competition for amazon. if you think about it, this is all directed at amazon. the tiktok deal is looking to rival amazon, four billion in ad

regeneron may have -- help reduce virus symptoms.ompany says the greatest benefit was in patients who had not mounted their own effective immune response. experimental antibody treatment could become a powerful tool in the fight against coronavirus. a wildfire in northern california's wine country is threatening thousands of homes, forcing the evacuation of an entire resort town. the glass fire has scorched more than 66 square miles, 70 thousand people are being forced to leave the area. more evacuations will be ordered. global news 24 hours a day on air and at bloomberg quicktake, powered by 2700 journalists and analysts in 120 countries. this is bloomberg. anna: thanks very much. let's get back to one of our top stories this morning, the update we got from shall. the energy business is a better title for these types of businesses these days. job reductions are going to total 7000 to 9000 by the end of 2026. that's the time horizon we are looking at. more detail coming through on who that is made up of. people who have already agree

len schleifer is doing his best to get everyone who is sick or knows someone who is sick in the regeneronthink that is such an important thing, but it is mono cloenl antibody. if you know somebody who has gotten it this is the one to go to it's lost in the shuffle, david. there's so many and they need a lot of arms. >> it shouldn't be again, i will come back to merck as well, ken frazier and what they're do there and pearl mudder with their anti-viral, expanding phase two, in phase three and rolling. these things are rolling ahead and they may end up being as important if not more than the vaccine. >> they will be much more important. >> if you have an oral anti-viral that's available, if you get sick, first of all, you will be sick so you will be inclined to take it as opposed to a vaccine that some people may have some resistance to, we hope not these are going to be very important and it does deserve us continuing to pay close attention, jim, and get updates. in fact, i'd like to get more of an update on the mark effort. >> i do think that the market will fade here again because the pe

i prefer to go with the antivirals, but regeneron is week gilead is the weakest stock in the cramer covidndex what i think is important is what does it mean for the reopening of america i think a lot of the recommendations we've seen including the airlines are a belief that we're going to get vaccines in this year and maybe things are going to start looking up for spending. david, i think that if you're waiting on a vaccine, would you stick with tiffany >> would you stick with -- i don't know you know, that's -- we're going to talk a lot about that momentarily, jim, because it's obviously a story we've been covering closely and a lot of fascinating developments there listen, we are only hoping for the vaccines to be as safe and effective as possible and get them as quickly as we possibly can. i agree with you whether it's antivirals they are going to potentially be a key and we have to keep an eye for those because they could change the complexion of the entire virus for many people if they are available and effective. >> carl, last night i had the governor on from rhode island. they had

another vaccine play antibodies from lily and regeneron and tests from abbott.abbott. they're doing crazy things tests in airport please how about a nationally recognized company with rigor, with rigor >> but you've got to get the tests still. you have to go where >> your pharmacists can do it. you go like this and put it in a credit card size thing 15 minutes later it shows up an your app then you go. go to the super bowls. get people back in the stadium >> you think it will happen? >> three months. >> three months? >> if the government hadn't bought audiotape 150 -- bought all 150 million of these things. i have to go >> don't go too far. a lot i want to talk to you about later. >>> good thursday morning. welcome to another hour of "squawk on the street. carl and morgan both have the morning off. let's give you a look at markets as we're a half hour into trading. and we're well off the lows. the s&p had not been down that much, but almost three quarters of a percent at one point. the nasdaq is recovering faang is up. many of the big technologies are up as well

showed some promise when you start parsing through the data we're expecting to see results from regenerony said by the end of september. so we're looking for that and you know, everybody continues to hope these will be really important tools in this battle >> meg, thank you so much for that by the way, we're off the lows but just softening again a little bit as we approach the close with the dow down 170 again. mike, what are the key things you've been focusing on in the internals? >> the internals again have somewhat outperformed the indices. if you look at the volume on the new york stock exchange, it certainly to the negative side the but only modestly so and despite the fact we have significant losses intraday down to those, you know, let's say month to date lows earlier and then also, if you look at the nasdaq 52-week highs versus lows, something you would tend to see if the market was really ku kind of in full selloff lows is the new lows starting to perk up there is a lot of lift in the nasdaq going into this phase but we're still making more new highs than lows. this number has be

, we will have the best testing from abbott labs, i believe that the lily therapeutic, i believe regenerone sure that the states don't go, you know, four months of bad state, four months of bad restaurant and we end up really having to restart the whole economy. just bridge it and i think that that's something that both the republicans and democrats would agree on if it weren't for an election year. >> right agreed >> jim, anyothk u. >> great interview. >> thanks, jim we will see you. thank you. we will see you in just a few minutes. i felt like... ...i was just fighting an uphill battle in my career. so when i heard about the applied digital skills courses, i'm thinking i can become more marketable. you don't need to be a computer expert to be great at this. these are skills lots of people can learn. i feel hopeful about the future now. ♪ chamath palihapitiya >>> good morning, and welcome to "squawk on the street," i'm david faber along with jim cramer, carl has the morning off this morning let's give you a look at futures as we get ready to trade 30 minutes from now of course, you can se